Union Korea Pharm Replaces Entire Board with Bukwang Pharma Nominees Under Rehabilitation Plan
Union Korea Pharm will hold an extraordinary general meeting on June 23, 2026 to remove all seven existing directors under the approved rehabilitation plan and appoint four new directors recommended by Bukwang Pharmaceutical.
The new inside director candidates are Seong Gwang-hyun and Kim Seong-su, executives at Bukwang Pharmaceutical, while outside director candidates are Professor Lim Jeong-su from Yonsei University and former Hyosung TNS advisor Min Byung-hwan, expected to enhance board transparency and normalize management.
This meeting does not involve capital changes or shareholder return policies, focusing solely on governance restructuring through a complete board replacement.
[AI Summary]Union Korea Pharm replaces all directors per the rehabilitation plan, installing a board nominated by Bukwang Pharmaceutical. This governance overhaul aims to stabilize the company and improve transparency, potentially boosting long-term value. Share price outlook depends on the speed of operational turnaround and earnings recovery.